Swedish CDMO recognised for its commitment to its French operations
![](/46/pdcnewsitem/04/94/48/leprix.jpg)
The Prix D'Excellence Awards ceremony - Thomas Eldered, Recipharm CEO collecting their award.
Recipharm's four French facilities now serve over 50 of its customers worldwide, including a number of top 20 pharma firms.
Recipharm has received the “le Prix d’Excellence 2017 - Spécial Sciences de la vie” in recognition for its commitment to its French operations. The award was presented by the Swedish Chamber of Commerce in France.
The award acknowledges examples of best practice in the Franco-Swedish business community. As part of the application process, Recipharm was assessed on its commercial success, profitability, technological innovation, quality and continued commitment to its operations in France.
Over the course of its 10-year history in France, Recipharm has increased its presence significantly and its operations in the country now account for 21% of the company’s overall sales, with 73% of those sales being exported across the globe.
Recipharm, which established its French operations in 2007, now operates four manufacturing facilities in the country, located in Fontaine-les-Dijon, Pessac, Monts and Kaysersberg. From these facilities, the CDMO provides a broad range of development and manufacturing services across areas including solid dosage formulation, sterile injectables manufacturing and blow-fill-seal capabilities to a global customer base.
Jean-François Hilaire, Executive Vice President Strategy and Global Integration at Recipharm said: “We established our French operations 10 years ago to cater for demand in Europe and offer easy market access to our customers. Since then we have acquired four sites and made substantial investments into our facilities, including an EUR 18 million investment in 2016 into our blow-fill seal capability in Kaysersberg to meet customer demand in the US, Turkey, Australia and Canada."
“Our French facilities now serve over 50 of our customers worldwide, including a number of top 20 pharma firms, and employ over 20% of our staff. We have ongoing plans to grow our operations in the country and hope to see this positive trajectory continue for many years to come.”
Thomas Eldered, CEO at Recipharm added “I am honoured that Recipharm has been acknowledged for our decade-long commitment to France. We have been very pleased with the development of our business there and I would like to thank the Swedish Chamber of Commerce in France for recognising this.”
![Recipharm AB](https://www.cphi-online.com/c247872th_S-comp247872.jpg)
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance